View Older Stories View More Recent Stories

Oct 7, 2019 06:51AM Akcea Therapeutics (AKCA), Pfizer (PFE) Announce Licensing Agreement for investigative antisense therapy AKCEA-ANGPTL3-L(Rx)
Oct 7, 2019 06:50AM Akcea and Pfizer Inc. Announce Licensing Agreement for investigative antisense therapy AKCEA-ANGPTL3-L(Rx)
Oct 7, 2019 06:50AM Akcea and Pfizer Inc. Announce Licensing Agreement for investigative antisense therapy AKCEA-ANGPTL3-L(Rx)
Oct 2, 2019 07:36AM Biogen (BIIB) Announces Landmark NURTURE Study of Infants with SMA Treated Pre-Symptomatically with SPINRAZA Published in Neuromuscular Disorders
Oct 2, 2019 07:30AM Landmark NURTURE Study of Infants with Spinal Muscular Atrophy (SMA) Treated Pre-Symptomatically with SPINRAZA® (nusinersen) Published in Neuromuscular Disorders
Sep 25, 2019 10:05AM Ionis to receive the CLSA's 2019 Pantheon DiNA™ Award for Company of the Year
Sep 23, 2019 07:12AM Akcea Therapeutics (AKCA) Reports Election of Michael J. Yang and Joseph ‘Skip’ Klein III to Board
Sep 23, 2019 07:00AM Akcea Announces CEO Transition and Elects Two New Board Members
Sep 18, 2019 07:34AM Biogen (BIIB) Reports Initiation of New Global Clinical Trial, DEVOTE, Evaluating Higher Dose of SPINRAZA (nusinersen) & Additional Data
Sep 18, 2019 07:30AM Biogen Advances Spinal Muscular Atrophy (SMA) Clinical Research with New Study Evaluating a Higher Dose of SPINRAZA® (nusinersen) and Additional Data in a Broad Range of Patients
Sep 18, 2019 07:30AM Biogen Advances Spinal Muscular Atrophy (SMA) Clinical Research with New Study Evaluating a Higher Dose of SPINRAZA® (nusinersen) and Additional Data in a Broad Range of Patients
Sep 16, 2019 07:02AM Akcea Therapeutics (AKCA) Reports Positive Phase 1 Results of AKCEA-TTR-LRx
Sep 16, 2019 07:00AM Positive Phase 1 Results of AKCEA-TTR-LRx Presented at the Heart Failure Society of America Annual Meeting
Sep 16, 2019 07:00AM Positive Phase 1 Results of AKCEA-TTR-LRx Presented at the Heart Failure Society of America Annual Meeting
Aug 29, 2019 07:00AM Akcea and Ionis to Present New Data for TEGSEDI and AKCEA-TTR-LRx at Two Upcoming Medical Meetings
Aug 29, 2019 07:00AM Akcea and Ionis to Present New Data for TEGSEDI and AKCEA-TTR-LRx at Two Upcoming Medical Meetings
Aug 28, 2019 07:05AM Ionis Pharmaceuticals to present at upcoming investor conferences
Aug 27, 2019 07:05AM Ionis licenses hepatitis B program to GSK
Aug 7, 2019 05:10PM New England Journal of Medicine Publishes Results from Pivotal Study of WAYLIVRA® (volanesorsen) in Patients with Familial Chylomicronemia Syndrome
Aug 7, 2019 05:10PM New England Journal of Medicine Publishes Results from Pivotal Study of WAYLIVRA® (volanesorsen) in Patients with Familial Chylomicronemia Syndrome
Aug 7, 2019 07:00AM Ionis Reports Second Quarter 2019 Financial Results
Aug 6, 2019 05:14PM Akcea Therapeutics (AKCA), Ionis (IONS) Announce BROADEN Study with WAYLIVRA in Patients with FPL Met its Primary Endpoint
Aug 6, 2019 04:05PM Akcea Reports Financial Results and Highlights for Second Quarter 2019
Aug 6, 2019 04:05PM Akcea and Ionis Report Top-line Results from the BROADEN Study with WAYLIVRA® (volanesorsen) in Patients with Familial Partial Lipodystrophy
Aug 6, 2019 04:05PM Akcea Reports Financial Results and Highlights for Second Quarter 2019
Aug 6, 2019 04:05PM Akcea and Ionis Report Top-line Results from the BROADEN Study with WAYLIVRA® (volanesorsen) in Patients with Familial Partial Lipodystrophy
Jul 30, 2019 07:05AM Ionis Pharmaceuticals to hold second quarter 2019 financial results webcast
Jul 29, 2019 07:00AM Akcea Therapeutics to Hold Second Quarter 2019 Financial Results Webcast
Jul 29, 2019 07:00AM Akcea Therapeutics to Hold Second Quarter 2019 Financial Results Webcast
Jul 16, 2019 07:00AM hATTR Compass™ Genetic Testing Program Continues to Expand and Enable Diagnosis and Treatment of Hereditary ATTR Amyloidosis One Year Following Launch
Jul 16, 2019 07:00AM hATTR Compass™ Genetic Testing Program Continues to Expand and Enable Diagnosis and Treatment of Hereditary ATTR Amyloidosis One Year Following Launch
Jul 1, 2019 07:32AM Biogen (BIIB) Announces New Data Further Establishing SPINRAZA as Foundation of Care in SMA for Broad Range of Patients
Jul 1, 2019 07:30AM Biogen Announces New Data Further Establishing SPINRAZA® (nusinersen) as a Foundation of Care in Spinal Muscular Atrophy for a Broad Range of Patients
Jul 1, 2019 07:30AM Biogen Announces New Data Further Establishing SPINRAZA® (nusinersen) as a Foundation of Care in Spinal Muscular Atrophy for a Broad Range of Patients
Jul 1, 2019 07:30AM Biogen Announces New Data Further Establishing SPINRAZA® (nusinersen) as a Foundation of Care in Spinal Muscular Atrophy for a Broad Range of Patients
Jun 26, 2019 07:00AM Akcea and Ionis Announce Upcoming Data Presentations at the 5th European Academy of Neurology Annual Congress
Jun 26, 2019 07:00AM Akcea and Ionis Announce Upcoming Data Presentations at the 5th European Academy of Neurology Annual Congress
Jun 20, 2019 04:38PM Akcea and Ionis Announce Upcoming Data Presentations at the 2019 Peripheral Nerve Society Annual Meeting
Jun 20, 2019 04:38PM Akcea and Ionis Announce Upcoming Data Presentations at the 2019 Peripheral Nerve Society Annual Meeting
Jun 18, 2019 07:05AM Ionis Pharmaceuticals to present at the BMO Prescription for Success Healthcare Conference
Jun 12, 2019 04:05PM Ionis announces appointment of Joan E. Herman to its board of directors
Jun 6, 2019 07:05AM Ionis Pharmaceuticals to provide corporate update and 30-year retrospective at its 2019 Annual Meeting of Stockholders
May 28, 2019 07:00AM Akcea Therapeutics to Present at Upcoming Investor Conferences
May 28, 2019 07:00AM Akcea Therapeutics to Present at Upcoming Investor Conferences
May 15, 2019 06:02AM Biogen (BIIB) Reports Positive Recommendation for SPINRAZA (nusinersen) from NICE for Funding with U.K.'s National Health Service
May 14, 2019 07:02PM Biogen’s SPINRAZA® (nusinersen) Receives Positive Recommendation from NICE for Funding in the United Kingdom for the Treatment of Infants, Children and Adults with Spinal Muscular Atrophy
May 14, 2019 07:02PM Biogen’s SPINRAZA® (nusinersen) Receives Positive Recommendation from NICE for Funding in the United Kingdom for the Treatment of Infants, Children and Adults with Spinal Muscular Atrophy
May 9, 2019 07:00AM Ionis reports first quarter 2019 financial results
May 8, 2019 04:05PM Akcea Reports Financial Results and Highlights for First Quarter 2019
May 8, 2019 04:05PM Akcea Reports Financial Results and Highlights for First Quarter 2019
View More Recent Stories View Older Stories